1. Pink Sheet
  2. >>Geography
  3. >>Europe

‘Let's Be Ambitious,’ EMA Official Says Of Tackling GDPR Issues In Clinical Trials

 
• By Vibha Sharma

The EU clinical trials transformation initiative that was introduced this year could help address the issues clinical trial sponsors face with data privacy legislation, according to a senior EMA official.

Hands typing on laptop computer at table with double exposure of online security virtual interface. Concept of data protection and blockchain.
EU GDPR has strict requirements for protecting the personal data of clinical trial participants • Source: Shutterstock

A senior European Medicines Agency official has highlighted how the nine-month-old Accelerating Clinical Trials in the EU (ACT EU) initiative could serve as a platform to address the challenges clinical trial sponsors face in complying with EU data privacy requirements in the General Data Protection Regulation (GDPR).

The “momentum of ACT EU” initiative should be harnessed to drive efforts on this front, according to Peter Arlett, head...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Europe

Engage With HTA Body NICE Before Submitting MAA, UK Govt Tells Companies

 
• By Neena Brizmohun

The government has explained how to navigate the UK’s regulatory and market access funding mechanisms.

EU Pharma Reform: Council Wants Strengthened Member State Powers On Drug Supply

 
• By Eliza Slawther

The Council of the EU’s vision for the pharma reform package includes a stronger role for member states regarding the supply of medicines and the prevention of indication-stacking for orphan drugs.

EU Sees Unified Pathway For Drug/IVD Studies As Key To Future Research Investment

 
• By Vibha Sharma

As the EU tests the feasibility of a radical “all-in-one” procedure for combined drug and IVD studies, sponsors are being urged to approach this novel framework with flexibility and openness.

EU CHMP Opinions And MAA Updates

 
• By Neena Brizmohun

This is an update of recommendations from the European Medicines Agency's Committee for Medicinal Products for Human Use on the authorization of new medicines in the EU, and updates on EU marketing authorization changes recommended by the CHMP.

More from Geography

Engage With HTA Body NICE Before Submitting MAA, UK Govt Tells Companies

 
• By Neena Brizmohun

The government has explained how to navigate the UK’s regulatory and market access funding mechanisms.

EU Pharma Reform: Council Wants Strengthened Member State Powers On Drug Supply

 
• By Eliza Slawther

The Council of the EU’s vision for the pharma reform package includes a stronger role for member states regarding the supply of medicines and the prevention of indication-stacking for orphan drugs.

Quotable: Top Experts On Policy Hot Topics

 
• By Anabel Costa-Ferreira

The Pink Sheet highlights recent comments and insights from pharma officials and executives on key issues we are covering.